... Dose selection and PoC decisions Integrate biomarker strategy into clinical protocols and operational plans Drive early biomarker de‑risking , a key priority in neuromuscular programs 3. Early Clinical Development (Phase 1/2) Co‑lead design and execution of early clinical studies Define: Dose escalation strategy Exposure–response framework Translational endpoints (biopsy, imaging, functional) Ensure TM leadership within Clinical Trial Teams (CTTs ...
Inserat ansehen